Psoriasis is a life-long condition that significantly diminishes health related quality of life (HRQOL) and may have long-term effects on patients' well-being. [3] [4] [5] However, biological therapy can considerably improve clinical outcomes and HRQOL of patients. [6] [7] [8] Alongside the beneficial clinical profile of biologics, high drug costs impose challenges for many countries in terms of reimbursement. An extensive study across 46 European countries in another chronic inflammatory disease (rheumatoid arthritis, RA) revealed that access to biologics is positively associated with countries' welfare; therefore, patients in lower income European countries have less access to biological drugs. 9 Two previous studies, focusing on use of biologics for inflammatory rheumatic conditions and inflammatory bowel diseases, reported considerable differences in biological treatment rates between countries in the Central and Eastern European (CEE) region. 10, 11 Nevertheless, no evidence is available from CEE in this area concerning psoriasis. Considering the differences in economic performance across CEE, one would expect more psoriasis patients treated with biologics in higher-income countries.
Either it is unclear whether the high costs of biologics are per se responsible for the low treatment rate of certain countries, or do other factors underpin the differences. In the next years, a series of biosimilar drugs are expected to be registered which offer price advantage compared to the original drugs. Thus, the increasing penetration of biosimilars may substantially modify the entire biological drug market, especially in CEE.
The purpose of this paper is, therefore, to provide an overview on the current use of biological drugs for the treatment of psoriasis patients in 6 CEE countries, namely Bulgaria, Croatia, the F o r P e e r R e v i e w 3 Czech Republic, Hungary, Poland, and Romania. First, we summarise the available literature data on the epidemiology and disease burden of psoriasis in CEE. Secondly, we provide country-specific utilisation data on biologics in psoriasis in the six CEE countries and compare reimbursement policies and guidelines regulating the treatment with biological drugs. Third, we investigate and discuss the potential reasons for inter-country differences and set against other selected chronic systemic inflammatory diseases from CEE. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Methods

Epidemiology and disease burden
A Medline-based literature review on the epidemiology and disease burden of psoriasis in CEE was conducted until the 31 st October 2014. In addition, authors provided data regarding ongoing studies and conference abstracts available on these topics from their own countries.
Biological treatment rates
Number of patients with biological treatment was obtained from different sources by country such as patient registries, health insurance databases, ministries of health, and national professional societies. Treatment rates were estimated by two different methods: (i) patients treated with biologics as a proportion of all psoriasis patients of a country and (ii) patients treated with biologics per 100,000 inhabitants. The latter method filters out potential bias due to the unknown country-specific epidemiology. Population data used were obtained from Eurostat Statistics Database. 12 Correlation between health expenditure (retrieved from The World Bank Databank 13 ) and the number of psoriasis patients on biological treatment was analysed for each country.
Reimbursement guidelines and policies
Data on reimbursement guidelines and policies were gathered through document analysis and pooling of country expertise. A common set of questions and issues, that pertains the regulation on use of original biologics and as well biosimilars, was sent out to experts in the six countries. Data were further validated and refined through consultation with other CEE Health Technology Assessment (HTA) experts and policy-makers, and through discussions among the authors. 
Results
Epidemiology
We identified three studies that investigated the epidemiology of psoriasis in the CEE region, so far. [14] [15] [16] Prevalence of psoriasis among adults was assessed only in Croatia. A nationwide study (year 1989) reported prevalence of adult psoriasis 1.55% and a study from Karlovac region (year 1991) observed a prevalence of 0.75%. 14, 15 In Romania (year 1999), prevalence of psoriasis was noted 0.25% among Romanian schoolchildren aged 6-12 years. 16 Nevertheless, up-to-date country-specific incidence and prevalence data including all agegroups from the CEE countries are still lacking. Thus, we had to rely on estimations in our analyses. No evidence was found supporting that a difference in epidemiology of psoriasis within CEE exists; therefore, assuming a common prevalence of 2% for all the six countries (prevalence in Europe varies between 0.73% and 2.9%) 17 we estimated that in 2013, more than 1.8 million people lived with psoriasis in the six countries (Table 1) .
Disease burden of psoriasis
Of the four psoriasis cost-of-illness studies that have been carried out in CEE countries and presented in 5 publications (Table 2) , only one study from Hungary has been published as a full-text paper in an English-language peer-reviewed journal, findings from other countries were merely published as conference abstracts. [18] [19] [20] [21] [22] Although the four studies had similar aims, direct comparison of the results is hampered by the different inclusion criteria, unknown proportion of patients on biologics, and costing methods.
Number of patients on biologics
A total of 4,591 psoriasis patients are receiving biologics in more than 73 centres of the six selected countries which is estimated to be 0.25% of all psoriasis patients (Table 1) . On average 5 psoriasis patients out of 100,000 inhabitants are treated with biologics embedding a 1.1-14.6-fold difference between the six countries. Bulgaria, Croatia, and Poland are lagging behind the other three countries in use of biologics ( Figure 1 ). A moderate correlation between number of patients treated with biologics per 100,000 inhabitants and countries' total expenditure on health revealed (r=0.50, p=0.802); however, it was not significant due to the small number of countries involved. Remarkably, Romania treats on average 7.9 patients per 100,000 inhabitants despite its rather low per capita health expenditure ($420). By contrast, as a respect of the higher per capita health expenditure of the Czech Republic ($1,432), on average 11.2 patients per 100,000 population, receiving biologics seems few. (Table 3) . Currently, biologics are reimbursed in all the six countries and are covered without co-payment for the patients. However, in Bulgaria the National Health Insurance Fund and the pharmaceutical companies share financing on 75/25 (Table 3 ). In the six countries, all the four aforementioned original biologics are reimbursed, with the exception of infliximab in Poland and ustekinumab in Romania.
Reimbursement of biologics
Reimbursement
In 2014, biosimilar infliximab drugs were begun to be marketed in Bulgaria, the Czech Republic, Hungary, and Romania, and are reimbursed at the same level as the original drug.
Nevertheless, the introduction is lagging in Croatia, Poland, and Romania.
Reimbursement guidelines
The six countries apply similar clinical eligibility criteria for reimbursement regarding biological therapy based on the recommendations of the European-S3 Guidelines 1, [23] [24] [25] Biologics are recommended in moderate to severe psoriasis patients who meet certain eligibility criteria expressed in Psoriasis Area and Severity Index (PASI), and/or Body Surface Area (BSA) and/or Dermatology Life Quality Index (DLQI) after being treated for at least 6 months with traditional systemic therapy or in case of these are not tolerated or contraindicated. 1 However, in financial guidelines, severity scores required to be eligible for reimbursed treatment are different from those in professional guidelines. 1, 26 In Bulgaria (PASI>20 or BSA>20), Croatia (PASI>15 and/or BSA>15 and/or DLQI>15), and Poland (PASI>18, DLQI>10, and BSA>10) eligibility criteria are rather restrictive and only patients 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   7 with higher severity scores (and worse health status) are allowed to treat with biologics, whereas in the Czech Republic, Hungary and Romania, criteria are closer to those in the European-S3 Guidelines (Table 3) . 1 In all countries, but Poland, first assessment of treatment effect is required at week 12 after the initiation of the biological therapy.
In most countries, maintenance therapy is allowed for patients who reach a response of ≥50% reduction in PASI, and in addition ≥5 points improvement in DLQI. Duration of treatment is unlimited, except for Poland, where adalimumab and ustekinumab can be applied up to 48 weeks and etanercept up to 24 weeks, respectively.
In all the six countries, switch between different biological substances (both original and biosimilar, where applicable) is allowed, if adverse events or inefficiency develop. Total health expenditure per capita of these 6 countries ($420-1,432) seems to partly explain a proportion of the differences in biologic use ( Figure 1 ). Reimbursement policies and guidelines may also obstacle the widespread use of biologics in certain countries. In Bulgaria,
Croatia, and Poland start of reimbursement was delayed 7-9 years compared to the Czech Republic and Hungary which commenced the reimbursement earliest among the six countries.
We believe therefore that the time since reimbursement decision is one of the factors that highly influences the treatment rates.
Besides, we found that use of biologics highly depends on eligibility criteria applied for reimbursement. The very high baseline PASI and DLQI scores required in Bulgaria, Croatia, and the somewhat lower in Poland largely explain the lower use observed in these countries (Table 3) . Contrarily, countries with less restrictive criteria, such as Romania and the Czech Republic, demonstrate considerably higher treatment rates. However, despite the less favorable criteria applied in Hungary (i.e. PASI>15 and DLQI>10), it holds the highest treatment rate out of the six countries. In case of Poland, the limited duration of treatment reimbursed may also hamper use of biologics. Furthermore, the lack of reimbursement of infliximab in Poland and ustekinumab in Romania to treat psoriasis as well might contribute to the lower biologic use of these countries. In addition, Croatia and Poland do not cover biosimilar infliximab, either.
It appears therefore that use of biologics for psoriasis in certain CEE countries, such as Bulgaria, Croatia, and Poland, is not hindered by the high costs of biologics, rather by the unfavourable reimbursement policies and guidelines. And if so, these countries with their fairly unsuitable conditions for the penetration of biologics, will presumably not benefit as much from the lower-cost biosimilars either, as they could if less restrictive eligibility criteria are employed.
Further challenges
In most CEE countries, fairly similar HTA-based decision-making is applied in reimbursement that requires economic evaluations. 34, 35 Disease burden of psoriasis patients treated with biological therapy is unknown in CEE countries except for Hungary (Table 2 ).
4,18
Annual individual direct costs of Hungarian moderate to severe psoriasis patients receiving biologics are in line with findings from Northern and Western Europe (€13,505-18,457).
36
As for cost-utility analyses, the international literature suggest that biologics are cost-effective alternatives for the treatment of psoriasis in countries such as UK, Germany, Sweden, Italy, the US, and Canada (£30,000-42,000/quality-adjusted life years -QALY). 37 In CEE, empirical country-specific data is only available from Poland; however, cost-effectiveness results are redacted in the publicly accessible documents. 38 Patients with moderate to severe psoriasis associated with psoriatic arthritis represent a further challenge of biological therapy in psoriasis, since biologics may be effective for both the skin and the joint condition. In randomised controlled trials (RCT) of biologics, the achieved average health gain measured by EQ-5D at week 12-54 were 0.12-0.21 in moderate to severe psoriasis and 0.24-0.28 in psoriasis associated with psoriatic arthritis. 6, 7, [40] [41] [42] Hence, from the viewpoint of health economics, in this patient group, cost-effectiveness of biologics might exceed that reported in psoriasis or in psoriatic arthritis separately which might support the increasing use of biologics.
22
Limitations
Possible limitation of this study is uncertainty of estimations due to lack of prevalence data from CEE. Patient numbers reported here do not include those patients who finance biologics for themselves, either those who receive the drugs within hospital budget, or under diagnosisrelated group-based (DRG) financing, or as a part of a compassionate programme of a pharmaceutical company. Nonetheless, experts state that the proportion of these patients could be considered marginal. In all countries but Hungary, patients on each substance include the switchers as well, and hence, the total number of patients is minimally overestimated. Also, comparison of country-specific reimbursement systems might be limited due to necessary simplifications.
Conclusions
To sum up, on average 0.25% of all psoriasis patients, or 5 psoriasis patients out of 100,000 inhabitants are treated with biologics. Use of biological treatment in CEE might be limited compared to Western and Northern Europe. With respect to the number of patients treated with biologics out of 100,000 inhabitants, a 14.6-fold difference was noted across the six countries; Bulgaria, Croatia, and Poland are lagging behind the other three countries in treatment rates. The significant differences among countries cannot be explained by variations in prices, cost-effectiveness, or budget impact of biologics. It seems that the time since reimbursement decision, the fewer number of reimbursed biologics, the more restrictive criteria to be eligible for reimbursed treatment in terms of baseline PASI and DLQI, and the maximum duration of treatment allowed are the factors that are responsible for the majority of the differences. Based on the available data, we presume that decision makers and payers less recognise psoriasis as a severe condition that can be successfully treated in a cost-effective manner. Our findings call for further research, including the implementation of local registries to follow-up patients, and disease burden and cost-effectiveness studies that may help to inform decision-makers about the true burden of psoriasis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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